Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHumanized antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced mAb targeting lymphocyte-activation gene 3 (LAG3; CD223)
Molecular Target Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationPsoriasis
Indication DetailsTreat plaque psoriasis
Regulatory Designation
PartnerPrima BioMed Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today